Alfasigma, a pharmaceutical company, completed the acquisition of Jyseleca business from Galapagos, a clinical-stage biotechnology company, for €170m. “We are very pleased to have signed a letter of intent with Galapagos and are excited to acquire the Jyseleca business. This transaction is an important development opportunity for both companies and represents another milestone in our journey of transformation and international growth, fitting into the core business areas of our company. We are delighted to welcome Galapagos' Jyseleca team into Alfasigma following completion of the process and look forward to working together to continue our path of innovation," Francesco Balestrieri, Alfasigma CEO.